| Literature DB >> 34906553 |
Somanjana Khatua1, Jesus Simal-Gandara2, Krishnendu Acharya3.
Abstract
Boosting or suppressing our immune system represents an attractive adjunct in the treatment of infections including SARS-CoV-2, cancer, AIDS, malnutrition, age related problems and some inflammatory disorders. Thus, there has been a growing interest in exploring and developing novel drugs, natural or synthetic, that can manipulate our defence mechanism. Many of such studies, reported till date, have been designed to explore effect of the therapeutic on function of macrophages, being a key component in innate immune system. Indeed, RAW264.7, J774A.1, THP-1 and U937 cell lines act as ideal model systems for preliminary investigation and selection of dose for in vivo studies. Several bioassays have been standardized so far where many techniques require high throughput instruments, cost effective reagents and technical assistance that may hinder many scholars to perform a method demanding compilation of available protocols. In this review, we have taken an attempt for the first time to congregate commonly used in vitro immune-modulating techniques explaining their principles. The study detected that among about 40 different assays and more than 150 sets of primers, the methods of cell proliferation by MTT, phagocytosis by neutral red, NO detection by Griess reaction and estimation of expression of TLRs, COX-2, iNOS, TNF-α, IL-6 and IL-1β by PCR have been the most widely used to screen the therapeutics under investigation.Entities:
Keywords: Anti-inflammation; Immune enhancing; Macrophage cell lines; Modern techniques; Primer sequences; Principle of methods
Mesh:
Year: 2021 PMID: 34906553 PMCID: PMC8665649 DOI: 10.1016/j.cbi.2021.109776
Source DB: PubMed Journal: Chem Biol Interact ISSN: 0009-2797 Impact factor: 5.192
Overview of some commonly used cell lines in immunomodulatory research [13,[29], [30], [31]]. The publication numbers were derived by searching in PubMed (https://www.ncbi.nlm.nih.gov/pubmed/) on November 18, 2021 using the following criteria: (i) RAW 264.7 AND immune activation; (ii) RAW 264.7 AND anti inflammation; (iii) J774 AND immune activation; (iv) J774 AND anti inflammation; (v) THP-1 AND immune activation; (vi) THP-1 AND anti inflammation; (vii) U937 AND immune activation; (viii) U937 AND anti inflammation; (vi) THP-1 AND anti inflammation; (ix) HL-60 AND immune activation; (x) HL-60 AND anti inflammation.
| Cell lines | RAW264.7 | J774.A1 | THP-1 | U937 | HL-60 |
|---|---|---|---|---|---|
| Source | BALB/c Mouse | BALB/c Mouse | Human | Human | Human |
| Establishing year | 1978 | 1968 | 1980 | 1976 | 1977 |
| Gender of the source | Male | Female | Male | Male | Female |
| Disease | Abelson murine leukemia virus-induced tumor | Reticulum sarcoma | Acute monocytic leukemia | Histiocytic lymphoma | Acute myeloid leukemia |
| Doubling time | ∼11 h | ∼17 h | ∼26 h | 48–72 h | 20–45 h |
| Growth mode | Semi-adherent | Semi-adherent | Suspension | Suspension | Suspension |
| Morphology | Loosely adherent, slightly spindle-shaped cells. Cells pile and become round shaped, when the culture is dense. | Round shaped cell with a large nucleus | Large, round single-cell morphology | Round shaped with short microvilli and a large beam-shaped nucleus | Round or ovoid, heterogeneous in size, occasionally express pseudopods |
| Other characters | High expression of iNOS in comparison with J774.A1 | Gene expression profile is closer to mice peritoneal macrophages than RAW 264.7. | High phagocytic ability and expression of cell surface markers such as TLR-2, CD36, CD-14, and CR3 163 (CD11b/CD18) | Bears t (10; 11) (p13; q14) translocation, constitutively express high level of cell-surface HLA class I molecules | Contains an amplified |
| Commonly used assays | Cell viability, phagocytosis, measurement of NO, ROS and cytokines production, morphological analysis, estimation of gene and protein expression | Cell viability, phagocytosis, measurement of NO and cytokines production, morphological analysis, immunoblotting | Cell viability, phagocytosis, measurement of NO, ROS and cytokines production, estimation of gene and protein expression | Cell viability, phagocytosis, measurement of NO and cytokines production, estimation of gene and protein expression | Cell viability, measurement of NO, ROS and cytokines production, western blotting |
| No. of publications in immune-stimulatory field | 2674 | 450 | 2519 | 1338 | 881 |
| No. of publications in anti-inflammatory field | 3843 | 175 | 1403 | 446 | 226 |
HLA: Human leucocyte antigen; NO: Nitric oxide; PMA: Phorbol-12-myristate-13-acetate; ROS: Reactive oxygen species; TLR: Toll-like receptor.
Fig. 1Schematic representation of assays available for the detection of cell viability/proliferation of macrophage.
Fig. 2Schematic representation of TLRs pathway in macrophage cells based on previous studies [15,17,44,70,82].
List of mouse specific primers to test immunomodulatory activity.
| Gene | Primer sequences | Tm (°C) | References |
|---|---|---|---|
| TLR-2 | F: 5′ AGCATCCGAATTGCATCACC 3′ | 55 | [ |
| F: 5′ CACCACTGCCCGTAGATGAAG 3′ | NM | [ | |
| F: 5′ GGGGCTTCACTTCTCTGCTT 3′ | NM | [ | |
| TLR-3 | F: 5′ GATACAGGGATTGCACCCATA 3′ | NM | [ |
| TLR-4 | F: 5′ TGTATTCCCTCAGCACTCTT 3′ | NM | [ |
| F: 5′ CGCTCTGGCATCATCTTCAT 3′ | NM | [ | |
| F: 5′ GGTGTGAAATTGAGACAATTGAAAAC 3′ | NM | [ | |
| F: 5′ TTGCTGCCAACATCATCCAG 3′ | 55 | [ | |
| F: 5′ CAGCTTCAATGGTGCCATCA 3′ | NM | [ | |
| F: 5′ GCCTTTCAGGGAATTAAGCTCC 3′ | NM | [ | |
| F: 5′ GGACTCTGATCATGGCACTG 3′ | NM | [ | |
| Dectin-1 | F: 5′ ACAGTACACCAGACACAGGG 3′ | NM | [ |
| CR3 | F: 5′ CCATGACCTTCCAAGAGAATGC 3′ | NM | [ |
| MYD88 | F: 5′ GCCAGAGTGGAAAGCAGTGT 3′ | 55 | [ |
| F: 5′ TGGCCTTGTTAGACCGTGA 3′ | NM | [ | |
| TRIF | F: 5′ TGGCAAACACCTTCAAGACA 3′ | NM | [ |
| NF-κB | F: 5′ ATGGCAGACGATGATCCCTAC 3′ | NM | [ |
| F: 5′ CAGACGATGATCCCTACGGAA 3′ | 60 | [ | |
| F: 5′ AGAAGGCTGGGGTCAATCTT 3′ | NM | [ | |
| IRG1 | F: 5′ GCTTTTGTTAATGGTGTTGCTG 3′ | NM | [ |
| iNOS | F: 5′ AGGGACTGAGCTGTTAGAGACA 3′ | 55 | [ |
| F: 5′ CTGCAGCACTTGGATCAGGAACCTG 3′ | 57 | [ | |
| F: 5′ CCCTTCCGAAGTTTCTGGCAGCAGC 3′ | 56–60 | [ | |
| F: 5′ CGGCAAACATGACTTCAGGC 3′ | NM | [ | |
| F: 5′ CATGCTACTGGAGGTGGGTG 3′ | NM | [ | |
| F: 5′ TTCCAGAATCCCTGGACAAG 3′ | NM | [ | |
| F: 5′ TTGTGCATCGACCTAGGCTGGAA 3′ | NM | [ | |
| F: 5′ GGTAGTAGTAGAATGGAGATAGG 3′ | NM | [ | |
| F: 5′ ATGGCTTGCCCCTGGAA 3′ | NM | [ | |
| F: 5′ TCCCTTCCGAAGTTTCTGGC 3′ | NM | [ | |
| F: 5′ CCTCCTCCACCCTACCAAGT 3′ | 60 | [ | |
| F: 5′ GCCCTGCTTTGTGCGAAGTGTCAG 3′ | NM | [ | |
| F: 5′ GAGCGAGTTGTGGATTGTC 3′ | 55 | [ | |
| F: 5′ AATGGCAACATCAGGTCGGCCATCACT 3′ | NM | [ | |
| F: 5′ CACCTTGGAGTTCACCCAGT 3′ | NM | [ | |
| F: 5′ ACGCTGAGTACCTCATTGGC 3′ | 62 | [ | |
| F: 5′ CTGGGACAGCACAGAATG 3′ | 55 | [ | |
| F: 5′ GAGCGAGTTGTGGATTGTC 3′ | 55 | [ | |
| F: 5′ CAACCAGTATTATGGCTCCT 3′ | 55 | [ | |
| F: 5′ GTCTTGCAAGCTGATGGTCA 3′ | 52 | [ | |
| F: 5′ CAAATCCTACCAAGTGACCTGAAAGAG 3′ | 56 | [ | |
| F: 5′ GTGCTGCCTCTGGTCTTGCAAGC 3′ | 55–60 | [ | |
| F: 5′ CCCTCCTGATCTTGTGTTGGA 3′ | NM | [ | |
| F: 5′ TGGGAATGGAGACTGTCCCAG 3′ | NM | [ | |
| TNF-α | F: 5′ ACCTGGCCTCTCTACCTTGT 3′ | 55 | [ |
| F: 5′ ATGAGCACAGAAAGCATGATC 3′ | 56 | [ | |
| F: 5′ GGGGATTATGGCTCAGGGTC 3′ | NM | [ | |
| F: 5′ AGTTCTATGGCCCAGACCCTC 3′ | 60 | [ | |
| F: 5ʹ TGGAACTGGCAGAAGAGGCA 3ʹ | NM | [ | |
| F: 5′ AGTGACAAGCCTGTAGCC 3′ | NM | [ | |
| F: 5′ CACGCTCTTCTGTCTACTG 3′ | NM | [ | |
| F: 5′ CATCCTCTCAAAATTCGAGTGACA 3′ | NM | [ | |
| F: 5′ AGCCCCCAGTCTGTATCCTT 3′ | NM | [ | |
| F: 5′ CAGGCGGTGCCTATGTCTC 3′ | NM | [ | |
| F: 5′ ATAGCTCCCAGAAAAGCAAGC 3′ | NM | [ | |
| F: 5′ GAACTGGCAGAAGAGGCACT 3′ | NM | [ | |
| F: 5′ GTGGAACTGGCAGAAGAGGC 3′ | 60 | [ | |
| F: 5′ ACTTCGGGGTGATCGGTC 3′ | 60 | [ | |
| F: 5′ TGCCTATGTCTCAGCCTCTTC 3′ | 55 | [ | |
| F: 5′ AGCACAGAAAGCATGATCCG 3′ | NM | [ | |
| F: 5′ ACAAGCCTGTAGCCCACG 3′ | NM | [ | |
| F: 5′ CACCCTTATTCTCGCTCAC 3′ | 53 | [ | |
| F: 5′ GGACTAGCCAGGAGGGAGAA 3′ | 55 | [ | |
| S: 5′ TGAGGCTGGATAAGATCTCAG 3′ | 60 | [ | |
| F: 5′ GGGCTACAGGCTTGTCACTCG 3′ | NM | [ | |
| F: 5′ AGCACAGAAAGCATGATCCG 3′ | NM | [ | |
| F: 5′ CCTGTAGCCCACGTCGTAGC 3′ | 55 | [ | |
| F: 5′ ATCAGTTCTATGGCCCAGAC 3′ | 54 | [ | |
| F: 5′ TTGACCTCAGCGCTGAGTTG 3′ | 55–62 | [ | |
| F: 5′ CGGGATCCATGAGCACAGAAAGCAT 3′ | NM | [ | |
| F: 5′ AACTTCGGGGTGATCGGTCC 3′ | NM | [ | |
| COX-2 | F: 5′ CCACTTCAAGGGAGTCTGGA 3′ | 60 | [ |
| F: 5′ CCCCCACAGTCAAAGACACT 3′ | 57 | [ | |
| F: 5′ GTACTGGCTCATGCTGGACGA 3′ | NM | [ | |
| F: 5′ GGTGCCTGGTCTGATGATG 3′ | NM | [ | |
| F: 5′ TCTGGAACATTGTGAACAACATC 3′ | NM | [ | |
| F: 5′ AGAAGGAAATGGCTGCAGAA 3′ | NM | [ | |
| F: 5′ AGGAGACATCCTGATCCTGGT 3′ | 60 | [ | |
| F: 5′ CACTACATCCTGACCCACTT 3′ | 55 | [ | |
| F: 5′ CCCCCACAGTCAAAGACACT 3′ | NM | [ | |
| F: 5′ TCTCAGCACCCACCCGCTCA 3′ | 55–60 | [ | |
| F: 5′ TGGTGCCTGGTCTGATGATG 3′ | NM | [ | |
| F: 5′ TGGACGAGGTTTTTCCACCAG 3′ | NM | [ | |
| F: 5′ TGATCGAAGACTACGTGCAAC 3′ | NM | [ | |
| IFN-α | F: 5′ CCTGTGTGATGCAGGAACC 3′ | NM | [ |
| IFN-β | F: 5′ ACTAGAGGAAAAGCAAGAGGA 3′ | NM | [ |
| IFN-γ | F: 5′ GATGCTCTTCGACCTCGAAACAGCAT 3′ | NM | [ |
| F: 5′ CTCAAGTGGCATAGATGT 3′ | NM | [ | |
| F: 5′ CCTCAAACTTGGCAATACTCA 3′ | NM | [ | |
| F: 5′ CCAAGTTTGAGGTCAACAAC 3′ | 55 | [ | |
| IL-1β | F: 5′ GCCACCTTTTGACAGTGATGAG 3′ | 55 | [ |
| F: 5′ AAGGAGCTATCACTTGACCAC 3′ | 60 | [ | |
| F: 5′ ATGGCAACTATTCCAGAACTCAACT 3′ | NM | [ | |
| F: 5′ GGCAGGCAGTATCACTCATT 3′ | NM | [ | |
| F: 5′ ATCTCGCAGCAGCACATC 3′ | NM | [ | |
| F: 5′ AAATACCTGTGGCCTTG 3′ | NM | [ | |
| F: 5′ AAGGGCTGCTTCCAAAC 3′ | NM | [ | |
| F: 5′ ACCTGCTGGTGTGTGACGTT 3′ | NM | [ | |
| F: 5′ CCTTGGGCCTCAAAGGAAAGAATC 3′ | NM | [ | |
| F: 5′ GGGCCTCAAAGGAAAGAATC 3′ | NM | [ | |
| F: 5′ AAGGAGACCAAGCAACGACAAAA 3′ | NM | [ | |
| F: 5′ CCTCGTGCTGTCGGACCCAT 3′ | 57–60 | [ | |
| F: 5′ GAGCTTCAGGCAGGCAGTAT 3′ | 60 | [ | |
| F: 5′ ATGGCAACTGTTCCAGAACTCAACT 3′ | NM | [ | |
| F: 5′ ATGGCAACTGTTCCTGAACTCAACT 3′ | NM | [ | |
| F: 5′ TGCAGAGTTCCCCAACTGGTACATC 3′ | 55 | [ | |
| F: 5′ TGCTTCCAAACCTTTGACCTGGGC 3′ | NM | [ | |
| F: 5′ AAGAAGAGCCCATCCTCTGT 3′ | 55 | [ | |
| F: 5′ CAAGGAGAACCAAGCAAC 3′ | 60 | [ | |
| F: 5′ TACAAGGAGAACCAAGCAACGACA 3′ | NM | [ | |
| IL-6 | F: 5′ TACTCGGCAAACCTAGTGCG 3′ | NM | [ |
| F: 5′ CAACGATGATGCACTTGCAGA 3′ | 55 | [ | |
| F: 5′ TTCCTCTCTGCAAGAGACT 3′ | 56 | [ | |
| F: 5′ GTCGGAGGCTTAATTACACA 3′ | 60 | [ | |
| F: 5′ GAGGATACCACTCCCAACAGACC 3′ | NM | [ | |
| F: 5′ AATTAAGCCTCCGACTTGTG 3′ | NM | [ | |
| F: 5′ CCGGAGAGGAGACTTCACAG 3′ | NM | [ | |
| F: 5′ GGAGTACCATAGCTACCTGG 3′ | NM | [ | |
| F: 5′ ATGAAGTTCCTCTCTGCAA 3′ | NM | [ | |
| F: 5′ TGGAGTCACAGAAGGAGTGGCTAAG 3′ | NM | [ | |
| F: 5′ TCCATCCAGTTGCCTTCTTG 3′ | NM | [ | |
| F: 5′ AGTTGCCTTCTTGGGACTGA 3′ | NM | [ | |
| F: 5′ CACTTCACAAGTCGGAGGC 3′ | 60 | [ | |
| F: 5′ CCGGAGAGGAGACTTCACAG 3′ | 60 | [ | |
| F: 5′ GGAGTACCATAGCTACCTGG 3′ | NM | [ | |
| F: 5′ GTACTCCAGAAGACCAGAGG 3′ | NM | [ | |
| F: 5′ AGTTGCCTTCTTGGGACTGA 3′ | NM | [ | |
| F: 5′ TTCCTCTCTGCAAGAGACTTC 3′ | 55 | [ | |
| F: 5′ TGCACTTGCAGAAAACAATC 3′ | 54 | [ | |
| F: 5′ GCTGGAGTCACAGAAGGAGTGGC 3′ | 55–60 | [ | |
| F: 5′ TGAACAACGATGATGCACTT 3′ | NM | [ | |
| F: 5′ ATGAAGTTCCTCTCTGCAAG 3′ | NM | [ | |
| F: 5′ GCCAGAGTCCTTCAGAGAGAGATACAG 3′ | NM | [ | |
| IL-10 | F: 5′ TGGCCCAGAAATCAAGGAGC 3′ | 60 | [ |
| F: 5′ TACCTGGTAGAAGTGATGCC 3′ | NM | [ | |
| F: 5′ CCAAGCCTTATCGGAAATGA 3′ | NM | [ | |
| F: 5′ GTGAAGACTTTCTTTCAAACAAAG 3′ | NM | [ | |
| IL-12 | F: 5′ CCACAAAGGAGGCGAGACTC 3′ | NM | [ |
| F: 5′ AACCAGACCCGCCCAAGAAC 3′ | NM | [ | |
| IL-12p35 | F: 5′ TCAGCGTTCCAACAGCCTC 3′ | 55 | [ |
| F: 5′ CTGCATCAGCTCATCGATGG 3′ | 55 | [ | |
| IL-12p40 | F: 5′ CAGAAGCTAACCATCTCCTGGTTT 3′ | 55 | [ |
| F: 5′ TCCGGAGTAATTTGGTGCTTCACA 3′ | 55 | [ | |
| IL-18 | F: 5′ ACTGTACAACCGCAGTAATACGG 3′ | 58 | [ |
| F: 5′ TGAACAACGATGATGCACTT 3′ | 58 | [ | |
| MKP-1 | F: 5′ GCATCCCTGTGGAGGACAACC 3′ | 55 | [ |
| MIP-2 | F: 5′ GAACAAAGGCAAGGCTAACTGA 3′ | NM | [ |
| MCP-1 | F: 5′ ACTGAAGCCAGCTCTCTCTTCCTC 3′ | NM | [ |
| F: 5′ GGAAAAATGGATCCACACCTTGC 3′ | NM | [ | |
| NOX-2 | F: 5′ ACCAGACAGACTTGAGAATG 3′ | NM | [ |
| CCL3 | F: 5′ TGCCCTTGCTGTTCTTCTCT 3′ | NM | [ |
| PTGIS | F: 5′ CAGACGACCACTCTCCCACAG 3′ | 60 | [ |
| Granzyme-B | F: 5′ AGATCGAAAGTGCGAATCTGA 3′ | NM | [ |
| Perforin | F: 5′ AGTCCTCCACCTCGTTGTCCGTGA 3′ | NM | [ |
| NKG2D | F: 5′ GACTTCACCAGTTTAAGTAAATC 3′ | NM | [ |
| FasL | F: 5′ CCAGAGAGAGCTCAGATACGTTGAC 3′ | NM | [ |
| GPR120 | F: 5′ GATGACAATGAGCGGCAGCG 3′ | NM | [ |
| GM-CSF | F: 5′ ACTCTGCTCACGAAGGAACTCAGC 3′ | NM | [ |
| LY96 | F: 5′ AATACCATTCTCTTTCGAGG 3′ | 60 | [ |
| 18s rRNA | F: 5′ TCGAGGCCCTGTAATTGGAA 3′ | NM | [ |
| F: 5′ CGCTCGCTCCTCTCCTACT 3′ | 55 | [ | |
| β-actin | F: 5′ CGCCACCAGTTCGCCATGGA 3′ | 60 | [ |
| F: 5′ TGGAATCCTGTGGCATCCATGAAAC 3′ | 55– | [ | |
| F: 5′ CATCTCTTGCTCGAAGTCCA 3′ | NM | [ | |
| F: 5′ GCTGTGCTATGTTGCTCTAG 3′ | NM | [ | |
| F: 5′ TCACCCACACTGTGCCCATCTACGA 3′ | NM | [ | |
| F: 5′ CCACAGCTGAGAGGGAAATC 3′ | NM | [ | |
| F: 5′ AGCCATGTACGTAGCCATCC 3′ | NM | [ | |
| F: 5′ ATCACTATTGGCAACGAGCG 3′ | NM | [ | |
| F: 5′ CCCTGTATGCCTCTGGTCGT 3′ | 60 | [ | |
| F: 5′ GCTGTCCCTGTATGCCTCT 3′ | 55 | [ | |
| F: 5′ GACGTTGACATCCGTAAAG 3′ | NM | [ | |
| F: 5′ GTGGGCCGCCCTAGGCACCAG 3′ | 62 | [ | |
| F: 5′ AACTGGAACGGTGAAGGTGA 3′ | 55 | [ | |
| F: 5′ AGGCATCCTGACCCTGAAGTAC 3′ | 52 | [ | |
| F: 5′ GGAGAAGATCTGGCACCACACC 3′ | 55 | [ | |
| F: 5′ AACCGTGAAAAGATGACCCAGAT 3′ | NM | [ | |
| F: 5′ GGACAGTGAGGCCAGGATGG 3′ | NM | [ | |
| GAPDH | F: 5′ GGTGAAGGTCGGTGTGAACG 3′ | 55 | [ |
| F: 5′ GGACTGTGGTCATGAGCCCTTCCA 3′ | NM | [ | |
| F: 5′ AACGGATTTGGCCGTATTGG 3′ | NM | [ | |
| F: 5′ ACCAGAGTCCATGCCATCAC 3′ | NM | [ | |
| F: 5′ AGAGTGTTTCCTCGTCCCGTA 3′ | 60 | [ | |
| F: 5′ TGTGTCCGTCGTGGATCTGA 3′ | 60 | [ | |
| F: 5′ ACAACTTTGGCATTGTGGAA 3′ | NM | [ | |
| F: 5′ TTTGTCAAGCTCATTTCCTGGTATG 3′ | NM | [ | |
| F: 5′ AACAGCAACTCCCACTCTTC 3′ | NM | [ | |
| F: 5′ CTCTGCTCCTCCCTGTTC 3′ | 52 | [ | |
| F: 5′ CACTCACGGCAAATTCAACGGCAC 3′ | 60 | [ | |
| F: 5′ TGTGATGGGTGTGAACCACGAG 3′ | NM | [ |
NM: Not mentioned.
List of human specific primers to test immunomodulatory activity.
| Gene | Primer sequences | Tm (°C) | References |
|---|---|---|---|
| NF-κB | F: 5′ GGTGCGGCTCATGTTTACAG 3′ | 60 | [ |
| IL-1β | F: 5′ TGATGGCTTATTACAGTGGCAATG 3′ | 60 | [ |
| F: 5′ GGCTTATTACAGTGGCAATG 3′ | 60 | [ | |
| F: 5′ GGGATAACGAGGCTTATGTGC 3′ | NM | [ | |
| F: 5′ CCCTCTGTCATTCGCTCCC 3′ | NM | [ | |
| IL-4 | F: 5′ TCTTTGCTGCCTCCAAGAAC 3′ | 60 | [ |
| IL-6 | F: 5′ CCAGCCTGCTGACGAAGC 3′ | 60 | [ |
| F: 5′ CACACAGACAGCCACTCACC 3′ | 60 | [ | |
| IL-8 | F: 5′ ACCACCGGAAGGAACCATCTC 3′ | 60 | [ |
| IL-10 | F: 5′ TTTAAGGGTTACCTGGGTTGC 3′ | 60 | [ |
| IFN-α | F: 5′ CAGCCTGGATAACAGGAGGA 3′ | 60 | [ |
| TGF-β | F: 5′ CACTTCATCAACCCGGAAAC 3′ | 60 | [ |
| TNF-α | F: 5′ CCCGACTATCTCGACTTTGC 3′ | 60 | [ |
| F: 5′ CGAGTCTGGGCAGGTCTA 3′ | NM | [ | |
| F: 5′ TGAGCACTGAAAGCATGATCC 3′ | NM | [ | |
| F: 5′ ATGAGCACTGAAAGCATGATCC 3′ | 60 | [ | |
| CSF-1 | F: 5′ GGAGACCTCGTGCCAAATTA 3′ | 60 | [ |
| CYP1A1 | F: 5′ TCCTGGAGCCTCATGTATT 3′ | 61 | [ |
| 18srRNA | F: 5′ CAGCCACCCGAGATTGAGCA 3′ | 61 | [ |
| β-actin | F: 5′ CACTCTTCCAGCCTTCCTTCC 3′ | 60 | [ |
| F: 5′ CACCATTGGCAATGA GCGGTTC 3′ | NM | [ | |
| GAPDH | F: 5′ GGTGGTCTCCTCTGACTTCAACAG 3′ | 60 | [ |
| F: 5′ GGAGCGAGATCCCTCCAAAAT 3′ | NM | [ |
NM: Not mentioned.